Skip to main content

Security report for redshiftbio.com

RedShift BioAnalytics, Inc. · Technology · United States

Medium risk. 3 critical or high findings in GDPR outside view and SSL/TLS.

Security score

72/100

Risk levelMedium

0–100, higher is better. How it is calculated

RedShift BioAnalytics, Inc. is a specialized technology company focused on providing advanced analytical instrumentation for protein and biomolecule analysis, primarily serving the biopharmaceutical industry. Their innovative solutions, including Microfluidic Modulation Spectroscopy (MMS) and the HaLCon platform, enable rapid, precise structural insights critical for drug discovery, development, and manufacturing. Positioned as an innovative and trusted provider, RedShiftBio targets biopharma companies and life science researchers with a medium-sized business footprint based in the United States. The company's digital infrastructure is built on a modern Webflow CMS platform, leveraging a suite of contemporary web technologies such as Google Tag Manager, Pardot marketing automation, and Cloudflare Turnstile captcha for security. The website demonstrates excellent performance, mobile optimization, and accessibility, reflecting a mature digital presence. Integration of multiple analytics and marketing tools indicates a moderate level of user tracking aligned with business growth objectives. From a security perspective, the website enforces HTTPS, employs bot protection mechanisms, and secures user input forms with captchas. However, it lacks explicit published security policies, incident response procedures, and vulnerability disclosure information, which are recommended to enhance trust and compliance. The absence of WHOIS registration data raises concerns about domain legitimacy, although the professional website content and business information mitigate some risk. Overall, RedShiftBio presents a professional and trustworthy online presence with strong technical implementation and business credibility. Strategic improvements in transparency around security policies and domain registration verification would further strengthen their security posture and stakeholder confidence.

Scanned

NIS2 and GDPR posture

GDPR outside view
53/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

3 findings rated critical or high. Fix these first.

  1. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Policy found

      GDPR requires clear information about cookie usage

      What to do: Add a dedicated cookie policy explaining cookie usage and purposes

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching redshiftbio.com

This scan found 22 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
72
Security headers
60
Email security
70
DNS health
75
Network security
100
GDPR outside view
53
Average
72

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

RedShiftBio operates in the niche market of biopharmaceutical analytical instrumentation, offering cutting-edge technologies that accelerate drug development workflows. Their business model is B2B, focusing on providing hardware and software solutions that deliver high-sensitivity biomolecule analysis. The company maintains a strong brand presence with consistent messaging and active engagement through news, events, and social media channels. Revenue streams likely include product sales, service contracts, and possibly licensing of proprietary technologies. The target customer segments are biopharma companies, academic researchers, and vaccine developers. Growth indicators include recent product launches and participation in industry events. The partnership ecosystem includes marketing and analytics service providers but no direct business partners or subsidiaries were identified from the data.

Security posture

The website demonstrates a good security maturity level with enforced HTTPS, use of modern captcha solutions to prevent automated abuse, and no visible exposure of sensitive data. The inclusion of multiple security-related scripts and analytics is managed without apparent vulnerabilities. However, the lack of published security policies, incident response contacts, and vulnerability disclosure mechanisms represents a compliance gap. There is no evidence of GDPR non-compliance, and cookie consent mechanisms are implemented. Incident response readiness and security culture indicators are not publicly documented, which could be improved to enhance transparency and trust.

Recommendations

  1. Publish a dedicated security policy page detailing security practices and compliance.
  2. Implement and publicize a vulnerability disclosure program or security.txt file.
  3. Provide clear incident response contact channels such as security@ or abuse@ email addresses.
  4. Verify and update WHOIS domain registration information to ensure transparency and trust.
  5. Regularly audit and update third-party scripts and dependencies to mitigate potential vulnerabilities.

Contact details published on the site

Addresses
Legal name
RedShift BioAnalytics, Inc.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
RedShift BioAnalytics, Inc.
Description
RedShiftBio delivers powerful tools for protein and biomolecule analysis, built for the demands of modern biopharma. From discovery to manufacturing, their technologies accelerate development by revealing critical structural data with unmatched speed and precision.
Key services
Protein and biomolecule structural analysis, Microfluidic Modulation Spectroscopy (MMS), Real-time titer measurement with HaLCon, Biophysical characterization of proteins and RNA
Content quality
excellent
Branding
consistent

Technology

Stack
Webflow CMS, Google Tag Manager, Google Analytics, Facebook Pixel, LinkedIn Feed Widget, Jetboost, GSAP Animation Library, Anime.js, jQuery, Cloudflare Turnstile Captcha, Pardot Marketing Automation
Frameworks
Webflow, GSAP
Platforms
Webflow Hosting
Performance
fast
Mobile
excellent
Accessibility
good
SEO
good

Security

Observed score
90/100
Good practices seen
  • HTTPS enforced
  • Use of Cloudflare Turnstile captcha for bot protection
  • No exposed sensitive data in HTML
  • Secure forms with reCAPTCHA and Turnstile
  • No outdated or vulnerable libraries detected

Analytics and tracking

Services
Google Analytics, Microsoft Clarity, Pardot
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Facebook Pixel, Microsoft Clarity, Pardot
Marketing tools
Pardot Marketing Automation, Jetboost
Transparency
good

Site quality

Design
excellent
User experience
excellent
Content relevance
excellent
Navigation
excellent
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is fully accessible with rich content and no blocking detected.
  2. Professional and modern design with clear navigation and branding.
  3. Strong focus on biopharma analytical instrumentation and services.
  4. Multiple forms with secure captcha implementations for lead capture.
  5. Comprehensive privacy and cookie policies present.
  6. No explicit security policy or incident response info found.
  7. WHOIS data missing, indicating possible domain registration or privacy issues.
  8. Use of multiple third-party marketing and analytics tools.
  9. No suspicious or malicious content detected.
Technical notes

Notes

The website is built on the Webflow CMS platform, utilizing a modern tech stack including GSAP for animations, Pardot for marketing automation, and Cloudflare Turnstile for bot mitigation. Performance is optimized with CDN usage and asynchronous script loading. The site is mobile responsive and accessible with good SEO practices including meta tags and structured data. Technical risks are minimal but include reliance on multiple third-party scripts which require ongoing monitoring. The absence of explicit security headers in the HTML source suggests potential for enhancement. Overall, the technical infrastructure supports a professional and performant web presence aligned with business goals.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with redshiftbio.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review redshiftbio.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.